The effects of simultaneous administration of dietary conjugated linoleic acid and telmisartan on cardiovascular risks in rats

Lipids

Volumn 42, Issue 9, 2007, Pages 855-864

  Abdullah, Mohammad M ^a   Xu, Zuyuan ^a   Pierce, Grant N ^a   Moghadasian, Mohammed H ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL RESEARCH CENTRE   (Canada)

Author keywords

Angiotensin II receptor blocker; Cardiovascular disease; Conjugated linoleic acid; Diabetes; Fatty acid; Metabolic syndrome; Obesity; Peroxisome proliferator activated receptor; Telmisartan

Indexed keywords

CHOLESTEROL; DISEASES; DRUG PRODUCTS; GLUCOSE; HEALTH RISKS; INSULIN; LIPIDS; MEDICAL PROBLEMS; METABOLISM; RATS;

CARDIOVASCULAR RISKS; CONJUGATED LINOLEIC ACIDS; METABOLIC SYNDROMES; OBESITY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS; TELMISARTAN;

FATTY ACIDS;

CHOLESTEROL; CONJUGATED LINOLEIC ACID; GAMMA INTERFERON; GLUCOSE; INSULIN; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; LIPID; LOSARTAN; NUTRACEUTICAL; TELMISARTAN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INTERFERON PRODUCTION; INTRAABDOMINAL FAT; LIPID BLOOD LEVEL; LIPID DIET; MALE; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASES; CYTOKINES; DIETARY SUPPLEMENTS; FRUCTOSE; INSULIN; INTRA-ABDOMINAL FAT; LINOLEIC ACIDS, CONJUGATED; LIPIDS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RISK FACTORS; TIME FACTORS;

ANIMALIA; RATTUS;

EID: 35348919470     PISSN: 00244201     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11745-007-3096-7     Document Type: Conference Paper

References (52)

1. Moller DE, Kaufman KD (2005) Metabolie syndrome: a clinical and molecular perspective. Annu Rev Med 56:45-62
2. Aude YW, Mego P, Mehta JL (2004) Metabolic syndrome: dietary interventions. Curr Opin Cardiol 19:473-479
3. Wang YW, Jones PJ (2004) Conjugated linoleic acid and obesity control: efficacy and mechanisms. Int J Obes Relat Metab Disord 28(8):941-955. Review
4. Houseknecht KL, Vanden Heuvel JP, Moya-Camarena SY, Portocarrero CP, Peck LW, Nickel KP, Belury MA (1998) Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty fa/fa rat. Biochem Biophys Res Commun 244(3):678-682
5. Kritchevsky D, Tepper SA, Wright S, Tso P, Czarnecki SK (2000) Influence of conjugated linoleic acid (CLA) on establishment and progression of atherosclerosis in rabbits. J Am Coll Nutr 19(4):472S-477S
6. Zulet MA, Marti A, Parra MD, Martínez JA (2005) Inflammation and conjugated linoleic acid: mechanisms of action and implications for human health. J Physiol Biochem 61(3):483-94. Review
7. Moya-Camarena SY, Van den Heuvel JP, Blanchard SG, Leesnitzer LA, Belury MA (1999) Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPAR-α J Lipid Res 40:1426-1433
8. Moya-Camarena SY, Van den Heuvel JP, Belury MA (1999) Conjugated linoleic acid activates peroxisome proliferator-activated receptor alpha and beta subtypes but does not induce hepatic peroxisome proliferation in Sprague-Dawley rats. Biochim Biophys Acta 1436:331-342
9. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-γ-modulating activity. Hypertension 43:993-1002
10. Pershadsingh HA, Kurtz TW (2004) Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care 27:1015
11. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW (2006) Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47:1003-1009
12. Moghadasian MH, McManus BM, Godin DV, Rodrigues B, Frohlich JJ (1999) Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action. Circulation 99:1733-1739
13. Moghadasian MH (2006) Dietary phytosterols reduce probucol-induced atherogenesis in apo E-KO mice. Atherosclerosis 188:28-34
14. Moghadasian MH, McManus BM, Nguyen LB, Shefer S, Nadji M, Godin DV, Green TJ, Hill J, Yang Y, Scudamore CH, Frohlich JJ (2001) Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans. FASEB J 15:2623-2630
15. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
16. Stark AH, Timar B, Madar Z (2000) Adaptation of Sprague Dawley rats to long-term feeding of high fat or high fructose diets. Eur J Nutr 39:229-234
17. Bhattacharya A, Rahman MM, Sun D, Lawrence R, Mejia W, McCarter R, O'Shea M, Fernandes G (2005) The combination of dietary conjugated linoleic acid and treadmill exercise lowers gain in body fat mass and enhances lean body mass in high fat-fed male Balb/C mice. J Nutr 135:1124-1130
18. Donnelly R, Ho H, Reaven GM (1995) Effects of low sodium diet and unilateral nephrectomy on the development of carbohydrate-induced hypertension. Blood Press 4:164-169
19. Naga K, Inoue N, Wang YM, Yanagita T (2003) Conjugated linoleic acid enhances plasma adiponectin level and alleviates hyperinsulinemia and hypertension in Zucker diabetic fatty (fa/fa) rats. Biochem Biophys Res Commun 310:562-566
20. Fortuno MA, Ravassa S, Etayo JC, Diez J (1998) Overexpression of Bax protein and enhanced apoptosis in the left ventricle of spontaneously hypertensive rats: effects of AT1 blockade with losartan. Hypertension 32(2):280-286
21. Schlenker EH, Shi Y, Wipf J, Martin DS, Kost CK Jr (2004) Fructose feeding and intermittent hypoxia affect ventilatory responsiveness to hypoxia and hypercapnia in rats. J Appl Physiol 97(4):1387-1394
22. Purves RD (1992) Optimum numerical integration methods for estimation of area-under-the-curve (AUC) and area-under-the-moment-curve (AUMC). J Pharmacokinet Biopharm 20(3):211-226
23. Watanabe M, Guo W, Zou S, Sugiyo S, Dubner R, Ren K (2005) Antibody array analysis of peripheral and blood cytokine levels in rats after masseter inflammation. Neurosci Lett 382:128-133
24. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716
25. Kurtz TW (2005) Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol 42(Suppl 1):S9-16
26. Yu Y, Correll PH, Van den Heuvel JP (2002) Conjugated linoleic acid decreases production of pro-inflammatory products in macrophages: evidence for a PPAR gamma-dependent mechanism. Biochim Biophys Acta 1581:89-99
27. Azain MJ, Hausman DB, Sisk MB, Flatt WP, Jewell DE (2000) Dietary conjugated linoleic acid reduces rat adipose tissue cell size rather than cell number. J Nutr 130:1548-1554
28. Yamasaki M, Mansho K, Mishima H, Kimura G, Sasaki M, Kasai M, Tachibana H, Yamada K (2000) Effect of dietary conjugated linoleic acid on lipid peroxidation and histological change in rat liver tissues. J Agric Food Chem 48:6367-6371
29. Choi JS, Jung MH, Park HS, Song J (2004) Effect of conjugated linoleic acid isomers on insulin resistance and mRNA levels of genes regulating energy metabolism in high-fat-fed rats. Nutrition 20:1008-1017
30. Ryder JW, Portocarrero CP, Song XM, Cui L, Yu M, Combatsiaris T, Galuska D, Bauman DE, Barbano DM, Charron MJ, Zierath JR, Houseknecht KL (2001) Isomer-specific antidiabetic properties of conjugated linoleic acid. Improved glucose tolerance, skeletal muscle insulin action, and UCP-2 gene expression. Diabetes 50:1149-1157
31. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H (2006) Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 48:51-57
32. Pí-Sunyer FX (2004) The epidemiology of central fat distribution in relation to disease. Nutr Rev 62:S120-126
33. West DB, Delany JP, Camet PM, Blohm F, Truett AA, Scimeca J (1998) Effects of conjugated linoleic acid on body fat and energy metabolism in the mouse. Am J Physiol 275:R667-672
34. West DB, Blohm FY, Truett AA, DeLany JP (2000) Conjugated linoleic acid persistently increases total energy expenditure in AKR/J mice without increasing uncoupling protein gene expression. J Nutr 130:2471-2477
35. Evans M, Geigerman C, Cook J, Curtis L, Kuebler B, McIntosh M (2000) Conjugated linoleic acid suppresses triglyceride accumulation and induces apoptosis in 3T3-L1 preadipocytes. Lipids 35:899-910
36. Tsuboyama-Kasaoka N, Takahashi M, Tanemura K, Kim HJ, Tange T, Okuyama H, Kasai M, Ikemoto S, Ezaki O (2000) Conjugated linoleic acid supplementation reduces adipose tissue by apoptosis and develops lipodystrophy in mice. Diabetes 49:1534-1542
37. Park Y, Storkson JM, Albright KJ, Liu W, Pariza MW (1999) Evidence that the trans-10, cis-12 isomer of conjugated linoleic acid induces body composition changes in mice. Lipids 34:235-2341
38. Sergiel JP, Chardigny JM, Sebedio JL, Berdeaux O, Juaneda P, Loreau O, Pasquis B, Noel JP (2001) Beta-oxidation of conjugated linoleic acid isomers and linoleic acid in rats. Lipids 36:1327-1329
39. He Y, Lam TH, Li LS, He SF, Liang BQ (2004) Triglyceride and coronary heart disease mortality in a 24-year follow-up study in Xi'an, China. Ann Epidemiol 14:1-7
40. Austín MA (1997) Triacylglycerol and coronary heart disease. Proc Nutr Soc 56:667-670
41. Li YQ, Ji H, Zhang YH, Ding DY, Ye XL (2006) Metabolic effects of telmisartan in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 373:264-2670
42. Fruchart JC (2001) Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. Am J Cardiol 88:24N-29N
43. Fruchart JC, Staels B, Duriez P (2001) PPARS, metabolic disease and atherosclerosis. Pharmacol Res 44:345-352
44. Henriksen EJ, Teachey MK, Taylor ZC, Jacob S, Ptock A, Kramer K, Hasselwander O (2003) Isomer-specific actions of conjugated linoleic acid on muscle glucose transport in the obese Zucker rat. Am J Physiol 285:E98-E105
45. Wilson PW (1997) An epidemiologic perspective of systemic hypertension, ischemic heart disease, and heart failure. Am J Cardiol 80:3J-8J
46. Nagao K, Inoue N, Wang YM, Hirata J, Shimada Y, Nagao T, Matsui T, Yanagita T (2003) The 10trans, 12cis isomer of conjugated linoleic acid suppresses the development of hypertension in Otsuka Long-Evans Tokushima fatty rats. Biochem Biophys Res Commun 306:134-138
47. Inoue N, Nagao K, Hirata J, Wang YM, Yanagita T (2004) Conjugated linoleic acid prevents the development of essential hypertension in spontaneously hypertensive rats. Biochem Biophys Res Commun 323:679-684
48. Sharpe M, Jarvis B, Goa KL (2001) Telmisartan: a review of its use in hypertension. Drugs 61:1501-1529
49. Haffner SM (2006) The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 97:3A-11A
50. O'Shea M, Bassaganya-Riera J, Mohede IC (2004) Immunomodulatory properties of conjugated linoleic acid. Am J Clin Nutr 79:1199S-1206S
51. Fichtischerer S, Breuer S, Heeschen C, Dimmeier S, Zeiher AM (2004) Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease. J Am Coll Cardiol 44:44-49
52. Pinderski Oslund LJ, Hedrick CC, Olvera T, Hagenbaugh A, Territo M, Berliner JA, Fyfe AI (1999) Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vase Biol 19:2847-2853